COMMUNIQUÉS West-GlobeNewswire

Proxygen Expands Platform Beyond Degradation to Build Next-Generation Induced Proximity Therapeutics
28/04/2026
Vienna, Austria, April 28, 2026 (GLOBE NEWSWIRE) -- Proxygen announces two lead programs approaching clinical development, p300 and CDK12, addressing multiple cancer types Vienna, Austria, April 28, 2026 – Proxygen, a [...]
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
28/04/2026
With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track [...]
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
28/04/2026
Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK [...]
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
28/04/2026
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be Led [...]
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
28/04/2026
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced [...]
Leadership Team Expansion to Support the Need for Healthier Employees
28/04/2026
TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Employers of all sizes are confronting unprecedented economic and geopolitical pressures that are resulting in crisis levels of employee burnout and mental health challenges. [...]
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
28/04/2026
SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12 [...]
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
28/04/2026
Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on defined development milestones WATERTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Kestrel [...]
Ritedose Reaches “1,000 Hours of Purpose”
28/04/2026
Employee-led initiative deepens Ritedose's commitment to Midlands nonprofits and the communities they serve COLUMBIA, S.C., April 28, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation today announced a significant [...]
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
28/04/2026
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place [...]
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
28/04/2026
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a [...]
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
28/04/2026
ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the Market Movers [...]
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
28/04/2026
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended [...]
Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
28/04/2026
Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA ™ ) technology [...]
Reacta Healthcare Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board
28/04/2026
DEESIDE, United Kingdom, April 28, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today [...]
Transactions in connection with share buy-back program
28/04/2026
Company announcement no. 12 - 26 28 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Holivita Launches a New Platform, Offering a Human-Centric Blueprint for Health Through AI and Your DNA
28/04/2026
DUBAI, United Arab Emirates, April 28, 2026 (GLOBE NEWSWIRE) -- Holivita , a forward-thinking med-tech company, announces the launch of its platform designed to support everyday health and self-care. “Health should no [...]
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
28/04/2026
OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancer Recruitment on track in OCTOPOD-IV, a Phase 1/2a multi-centre, multi- [...]

Pages